Wyeth

Pfizer Corporation

University of Pennsylvania

Riyez Karim

Lioudmila Tchistiakova

Xiang-Yang Tan

David S Howland

Margaret Maria Zaleska

Frank S Walsh

Pamela Kelley

Seung Poon Kwak

Menelas N Pangalos

Geertruida Machteld Veldman

Lisa Anne Collins-Racie

Kimberly Ann Marquette

Christopher John Corcoran

Edward Roland Lavallie

John Adam Nowak

William Kelley, Legal Representative

Erika L F Holzbaur-Howland

Nicholas Weber

Karen Wallace

Erika Lf Holzbaur-Howland

Lioudmila Gennadievna Tchistiakova

The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti-GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8-associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

Antibody to GDF8 and uses thereof

The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

Method for treating muscle wasting syndrome using antagonist antibodies against GDF-8

The disclosure provides novel molecules related to growth and differentiation factor 8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8 associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

Method for treating sarcopenia using antagonist antibodies against GDF-8

Method for treating cachexia using antagonist antibodies against GDF-8

Polynucleotides encoding antagonist antibodies against GDF-8

Method for treating muscular dystrophy using antagonist antibodies against GDF-8

Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8 associated disorders

Antagonist antibodies against GDF-8

Growing community of inventors

North Andover, MA, United States of America

Riyez Karim